We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

News

News

Qiagen Delivers the Human Druggable Genome siRNA Set

This second generation siRNA set enables gene silencing studies of 6992 potential human druggable targets.
News

Top NIH Prize Goes to Three Stanford Faculty Members

The Stanford winners are Thomas Rando, MD, PhD; Pehr Harbury, PhD, and Karl Deisseroth, MD, PhD.
News

Nanosphere Names Dr. Peter G. Schultz to Board of Directors

Dr. Schultz's widely recognized scientific knowledge will enable him to provide strategic guidance to Nanosphere.
News

Collaborations to Develop Applications Using HyperSense DNP Technology for NMR

Researchers will use HyperSense™ to identify biological markers for cancer, to develop methods for determining the kinetics and dynamics of protein-ligand interactions and for rapid characterization of compound libraries.
News

Galapagos and BioFocus Forms Biopharma Outfit

Galapagos hopes that its acquisition of BioFocus will accelerate its transition to a fully integrated drug development biopharmaceutical company.
News

DeltaNu Wins Prestigious R&D 100 Award

The product, released earlier this year by DeltaNu, is the Investigator which is used to follow high speed chemical reactions that are accelerated by microwaves.
News

Tecan at Biotechnica 2005

Visitors to the show will have opportunity to see the features on Tecan's Freedom EVO® series of automated workstations, the HS 400 Pro fully automated hybridization station, the high sensitivity LS Reloaded Scanner and the flexible Safire2 microplate reader.
News

Vion Licenses Heterocyclic Hydrazones

The hydrazones have unique chemical structures and biologic activity, and have shown potent cytotoxic activity in the National Cancer Institute's tumor cell panels and in vivo anticancer testing.
News

Renowned Neuroscientist Joins CytRx Scientific Advisory Board

Professor Burnstock, who played a major role in the development of CytRx's lead small molecule drug candidate arimoclomol, joins CytRx's Advisory Board.
News

Genzyme Expands Global Infrastructure for Manufacturing and Product Development

The expanded facilities will support Genzyme's continued growth and innovation, particularly in the areas of antibody and protein-based medicines.
Advertisement